On June 03, 2016 PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, reported that its entire senior management team will attend the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s (ASCO) (Free ASCO Whitepaper) 52nd annual meeting to be held June 3-7, 2016, at McCormick Place in Chicago (Press release, PharmaCyte Biotech, JUN 3, 2016, View Source [SID:1234512978]). The theme of this year’s meeting is "Collective Wisdom – The Future of Patient Centered Care and Research."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte Biotech, stated, "This year’s ASCO (Free ASCO Whitepaper) annual meeting will be invaluable as we head into the final preparations for our Phase 2b clinical trial in advanced pancreatic cancer. During ASCO (Free ASCO Whitepaper) we will host a medical and scientific discussion of our therapy for advanced pancreatic cancer among top oncologist investigators who have expressed interest in PharmaCyte’s technology and participation in our clinical trial. Joining me will be Dr. Gerald W. Crabtree, Dr. Matthias Löhr, Dr. Manuel Hidalgo, Prof. Dr. Walter H. Günzburg, Dr. Brian Salmons and Dr. Sanjay Batra. Presentations will be made by our Chief Scientific Officer, Dr. Günzburg, and Dr. Salmons – the co-developers of our Cell-in-a-Box live cell encapsulation technology. Presentations will also be made by Dr. Löhr and Dr. Hidalgo. Dr. Löhr is the Chairman of our Medical and Scientific Advisory Board (Board) and was the Principal Investigator of the two earlier clinical trials where our technology was found to be safe and effective in treating advanced pancreatic cancer. Dr. Hidalgo is a member of the Board and one of the principal architects of the design of our clinical trial."
ASCO is one of the largest organizations in the world devoted to the advancement of treatments for all types of cancer, and its annual meeting is the one of the largest educational and scientific meetings in the world. Over 32,000 individuals from around the globe have registered for this year’s meeting with over 50% of these from outside the United States. More than 26,000 of the total number of registrants are oncology professionals. Approximately 6,000 abstracts of presentations have been submitted for consideration by ASCO (Free ASCO Whitepaper). At this meeting, reports of studies on all types of cancer will be presented. For PharmaCyte, presentations on advanced pancreatic cancer and clinical trials will be of paramount importance.
In addition to scientists and clinicians, representatives from large and small pharmaceutical and biotech companies and Contract Research Organizations, all with an interest in cancer, will be in attendance. ASCO (Free ASCO Whitepaper)’s annual meeting provides representatives from all areas of the cancer spectrum the opportunity to interact and offers an unparalleled opportunity for the free exchange of information among meeting attendees.